We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...
SAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...
The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...
G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...
Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
2d
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback